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Abstract
Linear scleroderma is a form of localized scleroderma that primarily affects the pediatric population. When it occurs
on the scalp or forehead, it is termed “en coup de sabre”. In the en coup de sabre subtype, many extracutaneous
associations, mostly neurological, have been described. A patient with linear scleroderma en coup de sabre was
noted to have ipsilateral brain cavernomas by magnetic resonance imaging. Using a worldwide pediatric
rheumatology electronic list-serve, another patient with the same 2 conditions was identified. These two patients
are reported in this study. Consideration of neuroimaging studies to disclose abnormal findings in patients with
linear scleroderma en coup de sabre is important for potentially preventing and treating neurological
manifestations associated with this condition.
Background
Localized scleroderma encompasses the conditions of
linear scleroderma (LS) (extremity and facial), plaque or
circumscribed morphea, pansclerotic and generalized
morphea. By definition, localized scleroderma involves
the skin and underlying tissue. This is opposed to sys-
temic scleroderma, which not only involves skin but
includes internal damage to the lungs, gastrointestinal
tract, and vascular system.
Linear scleroderma is a form of localized scleroderma
that primarily affects the pediatric population. Up to
two-thirds of patients given this diagnosis are under the
age of 18, and males and females are equally affected
[1,2]. The lesions are typically sclerotic and discolored.
When these lesions occur on the scalp or forehead, they
are termed “en coup de sabre” [3-6]. In the en coup de
sabre subtype, extracutaneous associations, mostly neu-
rological, have been described [7]. However, internal
organ involvement beyond the central nervous system
(CNS) is extremely rare.
Linear scleroderma en coup de sabre is typically ipsi-
lateral and near the midline of the forehead with exten-
sion into the frontoparietal scalp. It can be associated
with hair loss and significant sclerosis of the skin. Often
en coup de sabre lesions coexist with Parry-Romberg
Syndrome (PRS), which involves hemiatrophy of the
subcutaneous tissue and bones of the face without skin
or scalp involvement [3-5,8].
The most commonly described brain lesions in LS en
coup de sabre are intracranial calcifications, which are
characteristically ipsilateral to the skin lesions, and
appear as hypointense white matter lesions on T2-
weighted magnetic resonance imaging (MRI) [5,6,9].
Hyperintense white matter lesions on T2-weighted MRI
are also commonly seen in these patients [10]. Other
neuroimaging abnormalities described in LS en coup de
sabre include cerebral hemiatrophy, hyperintensities in
deep white and gray matter structures, nonspecific
alterations in cerebral vasculature [11], and intracranial
aneurysms [12].
Cerebral cavernomas are vascular malformations
located in the central nervous system. They are present
in approximately 1 in 200 patients and approximately
20% of cavernomas are related to an autosominal domi-
nantly inherited familial disease. Cavernomas consist of
vessels that lack smooth muscle support and are thus
prone to rupture, which can cause hemorrhage, stroke,
seizures, or even death [13]. To our knowledge, there
have been no reports describing multiple cavernomas on
the ipsilateral side of a patient with LS en coup de sabre.
Herein, the diagnosis, treatment, and outcomes of two
patients with LS en coup de sabre and ipsilateral caver-
nomas at two large academic institutions are discussed.
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A patient with LS en coup de sabre at the Children’s
Hospital of Alabama was noted to have brain caverno-
mas by MRI. This child was one of 4 children with LS
en coup de sabre seen, among 59 LS and morphea
patients, over 10 years a this institution, and he was the
only one of the 4 LS en coup de sabre children imaged
with cavernomas by MRI. Using a worldwide pediatric
rheumatology electronic list-serve, another patient at the
The Hospital for Sick Children, Toronto, with the same
two conditions was identified. This unique child was
identified from among over 300 LS patients (~70 LS en
coup de sabre patients) seen over a 20 year period in
Toronto, and none prior with brain cavernomas. How-
ever, not all patients received neuroimaging. These two
patients are reported in this study.
Case #1
A 13-year-old white male, with LS/PRS since age 3, at
the Children’s Hospital of Alabama was referred to a
pediatric neurologist for the evaluation of two general-
ized tonic-clonic seizures initially treated with topira-
mate. There had been no preceding fever or trauma,
although the patient noted a 6-month history of worsen-
ing headaches. An EEG was normal, but an outside MRI
revealed effacement of sulci on the right side of his
brain. In addition, there was diffuse white matter
increased signal and T2 flair sequence on the right.
Finally, MRI showed multiple right-sided low densities
creating an echo sequence, likely representing microhe-
morrhage or calcification. Further diagnostic evaluation
was declined, and he was started on topiramate 50 mg
twice daily with no additional seizure activity noted. He
was then referred to a pediatric rheumatologist for
further evaluation and treatment. At initial evaluation 9
months later, an en coup de sabre lesion was noted near
the midline on right side of the face, extending from
nose to hairline and had become sunken per the family.
The lesion was noted to be hypopigmented with violac-
eous borders. There was an approximately 1.5 cm in
diameter and 0.5 cm in depth depression in the middle
of his head near the apex and just to the right of the
midline on the right side of the face (Figure 1). There
were no other lesions noted on his body nor was he sys-
temically ill. An ophthalmologic exam revealed no ocu-
lar inflammation. Upon presentation to rheumatology,
since the lesion appeared to be getting worse and head-
aches and seizures were ongoing, the patient was initi-
ally treated with prednisone 40 mg twice daily for one
month, tapered over the course of 2-3 months, and
methotrexate 25 mg injected subcutaneously each week.
Over the course of the next year the patient remained
on methotrexate, with doses ranging from 12.5 to 25 mg
weekly. On this treatment, the skin lesion improved (less
violaceous and less indurated) significantly. The patient
also remained seizure free during this time period. After
approximately 1 year of successful treatment, the family
chose to discontinue the methotrexate, and he remained
off of consistent treatment for the next year. Approxi-
mately 23 months after his initial seizure the patient
was noted to have a severe headache and the sudden
onset of left-sided hemiparesis and parathesias. An MRI
scan showed a 4 cm hemorrhage in the right frontopar-
ietal region with mass effect, areas of increased white
matter T2 signaling anterior to the lesion in the right
temporal lobe, and areas of signal drop out in a punctu-
ate fashion in many areas in the right hemisphere, most
consistent with multiple right-sided cavernomas. How-
ever, other primary vascular lesions cannot be formally
r u l e do u tw i t h o u tb i o p s y .Ac o n c o m i t a n tM R I / M R A
(MR angiogram) showed the same (Figure 2). Surgical
intervention was declined, but there was ongoing con-
cern for CNS inflammation, and the patient was
admitted to the pediatric intensive care unit and started
on topiramate, mycophenolate mofetil (MMF), and pre-
dnisone. The patient had residual focal neurological def-
icits, but otherwise did well and was discharged to
home on MMF 1,500 mg twice daily, prednisone 40 mg
daily, and topiramate 50 mg daily. The prednisone was
weaned over the course of 3 months. The patient
remained on MMF, and doses were gradually decreased
to 1,500 mg daily over the course of 8 months. The skin
lesion remained stable, but, the patient had a recurrent
partial seizure 6 months after his hemorrhage, described
as an episode of left arm and leg flexion lasting 3-4 min-
utes. There were no focal neurological changes, and the
patient’s topiramate was increased to 100 mg daily. The
Figure 1 En coup de sabre lesion. A digital photographic image
of the linear scleroderma/en coup de sabre lesion early in the
course of therapy for case #1.
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was treated with extensive physical rehabilitation and
made significant improvement, although his left lower
extremity continues to have spasticity. On motor testing
he does have mild left hemiparesis on his face, arm, and
leg. It is most prominent in his arm, and it is more evi-
dent distally than proximally. He walks with a mild
hemiparetic gait, and his right side strength remains
good. Throughout the course of his two years of treat-
ment at Children’s Hospital of Alabama, the patient
tested negative for an elevated erythrocyte sedimentation
rate or C-reactive protein, anti-nuclear antibody, rheu-
matoid factor, Scleroderma-70 antibody, double-
stranded DNA antibody, lupus anticoagulant, anti-neu-
trophil cytoplasmic antibody, cardiolipin antibody, and
Sjogren syndrome A and B antibodies.
Case #2
A 9 year-old-girl was referred to the Dermatology Clinic
at The Hospital for Sick Children with a 6-month history
of two facial lesions, one involving the right forehead and
the second involving the right cheek. This began as a
dime-sized lesion on the cheek and spread. There was no
history of preceding infection, trauma, or travel. There
were no headaches or ocular symptoms and she was
otherwise well. Examination showed a linear lesion invol-
ving the right side of the forehead with a central white
thickened sclerotic area surrounded by a violaceous rim.
A similar plaque was located on the right cheek and had
a similar appearance. The eye socket was spared. An
ophthalmologic evaluation excluded uveitis. A diagnosis
of facial morphea was made and treatment instituted
with intravenous methylprednisolone, 30 mg/kg/dose,
3 daily doses given 4 weeks apart for 3 courses. In addi-
tion, prednisone 1 mg/kg initially in a twice-daily dose
was started and weaned over 6 months. Methotrexate
15 mg/m
2 once a week was started together with 1 mg
folic acid per day. On this treatment, the lesions
improved significantly; there was softening, the violac-
eous discoloration disappeared, and the lesion became
smaller. Because of some mild remaining firmness in the
linear lesion, eight months later the methotrexate was
increased to 20 mg once a week and given subcuta-
neously. Three years later, the methotrexate began to be
weaned. She had no new lesions or progression of the
initial lesions during her course of treatment. She had
two minor elevations of her liver transaminases which
resolved spontaneously, and several oral ulcers which
resolved quickly while holding the methotrexate for one
week. Two months after the initial wean of the metho-
trexate, the patient complained of numbness of her left
h a n da n df o o t .S h eh a da nu n - w i t n e s s e df a l lb u tt h e n
seemed to be well and attended school. Several hours
later she had a secondarily generalized tonic-clonic sei-
zure which began on the left side. It required diazepam
for control. There had been no preceding fever or
trauma. A general physical exam was normal. Ophthal-
mologic evaluation was normal. She was treated with
phenytoin and dexamethasone. A CT scan demonstrated
a1 . 8×2 . 0c mh i g hd e n s i t yl e s i o ni nt h er i g h tp a r i e t a l
lobe, most likely representing hemorrhage without signif-
icant enhancement. There was a moderate amount of
surrounding vasogenic edema and no evidence of infarc-
tion. A concomitant MRI also revealed multiple smaller
low signal lesions on gradient echo T2 imaging suggest-
ing that the lesion most likely represented a cavernoma
that had bled. An MRI done 9 days later revealed that the
lesion had decreased dramatically in size and the edema
had resolved. There were multiple additional smaller foci
involving the right cerebral hemisphere likely represent-
ing calcification or hemosiderin due to other small caver-
nomas. The patient was discharged on carbamazepine,
has remained seizure free, and has done extremely well.
Her neurologic examination was normal and there were
no cognitive deficits.
Discussion
Multiple case studies have been published describing
neurological dysfunction in associated with LS. Typically
the skin lesion develops prior to the onset of neurologi-
cal symptoms, although cases of the reverse have cer-
tainly been described [1]. A literature review done by
Kister et al. found that the skin lesion preceded the
onset of neurological symptoms by an average of several
Figure 2 Brain cavernomas. Coronal cut MRI image of the brain
cavernomas located ipsilateral and directly beneath the en coup de
sabre linear scleroderma lesion of case #1.
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rological symptoms onset at age 13.8 years +/- 10),
although in 29% of the patients studied the two
occurred within one year of each other [7]. Often times
a patient with LS has been incidentally found to have
abnormalities on neurological imaging, even when there
are no neurological symptoms present [5,14]. With
regards to the two patients described above, one
patient’s appearance of skin lesion and CNS symptoms
was 10 years apart, while the other patient’sw a s3y e a r s
between. In both cases the skin lesion preceded the
onset of neurologic symptoms.
Many case studies have described the association
between LS and neurologic abnormalities. A case study in
2002 described a patient with LS and progressive atrophy
of the ipsilateral cerebral hemisphere, not associated with
overlying facial lesions [15]. Another in 2009 described a
patient with refractory partial seizures prior to the devel-
opment of a skin lesion on his head [16]. A ten-year old
boy with PRS and progressive neurological deficit was
found to have a giant intracranial aneurysm [10]. A case
study in 1999 reported a patient who had de novo forma-
tion of a cavernoma three months after beginning immu-
nosuppressive therapy with methotrexate; however, this
patient was known to have a venous malformation [17].
Nevertheless, to the knowledge of the authors, these 2
cases represent the first time the finding of LS en coup de
sabre with associated ipsilateral multiple brain cavernomas
has been described. There is certainly a possibility that
these two findings are unrelated and simply occurred by
chance, but secondary to the ipsilateral nature of these
two clinical findings, it is considerably more likely that
there is in fact an association between the two.
The association between LS and associated neurological
involvement on the ipsilateral side has been documented.
A study of 55 neurologically symptomatic patients with LS
showed that 78% had CNS lesions only on the side of the
skin lesion [7]. Two similar case studies of neurologically
asymptomatic patients with LS who received CNS imaging
showed that 82-100% (n = 13) had exclusively ipsilateral
lesions in the brain [18,19].
The pathogenic mechanisms behind neurological dys-
function associated with LS and PRS are unclear,
although several theories have been proposed. Perhaps
the most plausible and widely accepted explanation is
the “neurovasculitis hypothesis” based on focal MRI
findings and angiographic evidence of CNS vascular
changes [20-22]. Many physicians believe that LS
belongs in the collagen-vascular group of autoimmune
diseases, such as discoid and systemic lupus erythemato-
sus [23]. Alternatively, because neurologic abnormalities
in LS en coup de sabre and PRS typically occur on the
ipsilateral side, others believe that a defect in a common
cell progenitor led to early malfunction affecting one
side of the rostral tube during early neurological devel-
opment [24]. Still others believe that an infectious
source (such as B. burgdorferi)c o m b i n e dw i t hp r e d i s -
posing genetic factors may be responsible for the etiol-
ogy [3,4]. However, there does not appear to be an
association with brain cavernomas and lupus or Lyme
disease. Finally, it is interesting to speculate that factors
leading to increased angiogenesis in the brain [25] may
be related to increased angiogenesis in localized forms
of scleroderma [26].
Neuroimaging studies should be considered in all
patients with LS en coup de sabre at the time of diagno-
sis. In patients with any neurological signs or symptoms,
these imaging studies become necessary [15]. Alter-
nately, for patients with partial seizures, a thorough
facial and scalp exam should be completed to look for
skin changes associated with LS. Since neurological
abnormalities can manifest themselves at differing points
d u r i n gt h ec o u r s eo fd i s e a s e, it is important to have
careful follow-up in patients with LS en coup de sabre
as this may help direct theapy
Two different treatment approaches were employed for
the cases reported herein. For patient #1, there was con-
cern for ongoing inflammation so increased immunosup-
pression was employed. Dose reduction in MMF was
eventually required secondary to diarrhea and weight loss.
By contrast, the linear scleroderma in patient #2 was felt
to be inactive and potentially unrelated to the cavernoma.
Seizure management was the mainstay of therapy.
Whether or not continued immunosppression would have
helped prevent the CNS events reported herein remains
unclear, but the risk benefit ratio of immunosuppression
needs to be considered for each patient. In addition, stu-
dies in man and in rats suggest that immunosuppression
can improve neurologic outcomes following aneurismal
bleeds in the CNS [27,28]. Further study is warranted on
the role of immunosuppressive therapy in preventing and
treating CNS bleeds in individuals with CNS cavernomas.
Conclusions
En coup de sabre LS has known ipsilateral CNS associa-
tions. Herein, we report the first associations with ipsi-
lateral CNS cavernomas. In both cases presented, the
cavernomas bled with notable clinical manifestations. At
present, it is unclear whether these bleeds were asso-
ciated with ongoing inflammation as part of the LS.
Nevertheless, these cases highlight the importance of
CNS imaging in children with en coup de sabre LS.
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